ABCAM Plc Blocklisting Interim Review (1309W)
August 14 2015 - 8:57AM
UK Regulatory
TIDMABC
RNS Number : 1309W
ABCAM Plc
14 August 2015
For immediate release 14 August
2015
ABCAM PLC
("Abcam" or "the Company")
Block Admission Return
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, makes the following
notification pursuant to Schedule Six of the AIM Rules for
Companies regarding its existing block admission arrangements:
Name of applicant: Abcam plc
Name of scheme: 1. Abcam EMI Scheme
2. Abcam SAYE Scheme
3. Abcam 2005 Share Option Scheme
4. Abcam Share Incentive Plan
5. Abcam Company Share Option Plan
6. Abcam Long Term Incentive Plan
7. Annual Bonus Plan
----------------------------------------
Period of return: From: 6 February 2015 To: 7 August 2015
------------------------------ ----------------- ----- --------------
Balance of unallotted securities under scheme(s) from previous return: 1. 560,915
2. 31,405
3. 2,660,309
4. 281,146
5. 683,238
6. 1,965,749
7. 399,479
----------------------------------------
Plus: The amount by which the block scheme(s) has been increased since the date of the 1. -
last 2. -
return (if any increase has been applied for): 3. -
4. -
5. -
6. -
7. -
----------------------------------------
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 1. -
2. -
3. 133,504
4. -
5. 53,056
6. -
7. -
----------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1. 560,915
2. 31,405
3. 2,526,805
4. 281,146
5. 630,182
6. 1,965,749
7. 399,479
----------------------------------------
Name of contact: Laura Taylor, Investor Relations
Telephone number of contact: 01223 696000
---------------------------------
For further information please contact:
+ 44 (0) 1223
Abcam 696 000
Jeff Iliffe, Chief Financial Officer
Laura Taylor, Investor Relations Manager
J.P.Morgan Cazenove - Nominated Adviser & Joint + 44 (0) 20 7742
Corporate Broker 4000
James Mitford / Alex Bruce - Nominated Adviser
+ 44 (0) 20 7418
Peel Hunt LLP - Joint Corporate Broker 8900
Clare Terlouw / Jock Maxwell MacDonald - Corporate
Broking
+44 (0) 20 3727
FTI Consulting 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science
research tools, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level and improving the understanding of health and
disease.
Abcam is committed to providing scientists with an extensive
choice of reagents and tools, with the most comprehensive, honest
and up-to-date datasheets and customer reviews, fast delivery and
helpful customer service & technical support. The Company's
catalogue evolves with scientific research trends and is growing
each year to provide customers with products to meet their research
needs. The range now includes primary and secondary antibodies,
proteins, peptides, lysates, biochemicals, immunoassays and other
kits. Abcam also supports its customers by hosting a range of
global scientific events, forums and webinars, providing
opportunities for scientists to get together and present their
work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices enabling local services and multi-language support and
sells to over 100 countries. The Company was founded in 1998, and
now employs over 750 people. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRBDGDILUBBGUS
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024
